BioCentury | Apr 15, 2013
Strategy

IP armamentarium

...the same time period, Marina Biotech Inc. has done six deals. Marina (formerly MDRNA Inc. and Nastech...
BioCentury | Mar 29, 2011
Financial News

Marina planning follow-on

...through the sale of units in a follow-on. Further details were not disclosed. Marina (formerly MDRNA Inc....
BioCentury | Aug 30, 2010
Company News

Cypress, Marina Biotech deal

...up front and is eligible for $27 million in milestones, plus single-digit royalties. Marina (formerly MDRNA Inc....
...interfering RNA-based therapeutics, said the intranasal formulation of carbetocin was developed by its predecessor company, Nastech...
BioCentury | Aug 23, 2010
Company News

Cequent, Marina Biotech deal

...Marina (formerly MDRNA Inc. ) disclosed in its 2Q10 earnings that it completed its previously announced acquisition...
BioCentury | Aug 2, 2010
Company News

Marina Biotech, novosom deal

...Marina (formerly MDRNA Inc. ) acquired novosom's Smarticles liposomal-based delivery technology for 1.4 million shares of Marina...
BioCentury | Aug 2, 2010
Financial News

Marina Biotech financial update

MDRNA Inc. implemented a 1-for-4 reverse stock split, changed its name to Marina Biotech Inc. and began trading under the symbol "MRNAD." Following the split, the company will have 12.2 million shares outstanding. Marina Biotech...
BioCentury | Aug 2, 2010
Company News

Marina Biotech, University of Helsinki deal

...Marina (formerly MDRNA Inc. ) and the university extended by two years to June 2012 a 2008...
BioCentury | Jun 14, 2010
Company News

MDRNA, RiboTask deal

...technology to a 2009 deal granting MDRNA rights to use the technology for human therapeutics. MDRNA...
...technology for use in reagents. Financial terms were not disclosed (see BioCentury, June 29, 2009). MDRNA Inc....
BioCentury | May 17, 2010
Clinical News

MDRNA preclinical data

...DiLA2 liposome formulation. UsiRNAs are duplex small interfering RNAs modified with unlocked nucleobase analogs (UNA). MDRNA Inc....
BioCentury | May 17, 2010
Clinical News

MDRNA preclinical data

...DiLA2 liposome formulation. UsiRNAs are duplex small interfering RNAs modified with unlocked nucleobase analogs (UNA). MDRNA Inc....
Items per page:
1 - 10 of 321
BioCentury | Apr 15, 2013
Strategy

IP armamentarium

...the same time period, Marina Biotech Inc. has done six deals. Marina (formerly MDRNA Inc. and Nastech...
BioCentury | Mar 29, 2011
Financial News

Marina planning follow-on

...through the sale of units in a follow-on. Further details were not disclosed. Marina (formerly MDRNA Inc....
BioCentury | Aug 30, 2010
Company News

Cypress, Marina Biotech deal

...up front and is eligible for $27 million in milestones, plus single-digit royalties. Marina (formerly MDRNA Inc....
...interfering RNA-based therapeutics, said the intranasal formulation of carbetocin was developed by its predecessor company, Nastech...
BioCentury | Aug 23, 2010
Company News

Cequent, Marina Biotech deal

...Marina (formerly MDRNA Inc. ) disclosed in its 2Q10 earnings that it completed its previously announced acquisition...
BioCentury | Aug 2, 2010
Company News

Marina Biotech, novosom deal

...Marina (formerly MDRNA Inc. ) acquired novosom's Smarticles liposomal-based delivery technology for 1.4 million shares of Marina...
BioCentury | Aug 2, 2010
Financial News

Marina Biotech financial update

MDRNA Inc. implemented a 1-for-4 reverse stock split, changed its name to Marina Biotech Inc. and began trading under the symbol "MRNAD." Following the split, the company will have 12.2 million shares outstanding. Marina Biotech...
BioCentury | Aug 2, 2010
Company News

Marina Biotech, University of Helsinki deal

...Marina (formerly MDRNA Inc. ) and the university extended by two years to June 2012 a 2008...
BioCentury | Jun 14, 2010
Company News

MDRNA, RiboTask deal

...technology to a 2009 deal granting MDRNA rights to use the technology for human therapeutics. MDRNA...
...technology for use in reagents. Financial terms were not disclosed (see BioCentury, June 29, 2009). MDRNA Inc....
BioCentury | May 17, 2010
Clinical News

MDRNA preclinical data

...DiLA2 liposome formulation. UsiRNAs are duplex small interfering RNAs modified with unlocked nucleobase analogs (UNA). MDRNA Inc....
BioCentury | May 17, 2010
Clinical News

MDRNA preclinical data

...DiLA2 liposome formulation. UsiRNAs are duplex small interfering RNAs modified with unlocked nucleobase analogs (UNA). MDRNA Inc....
Items per page:
1 - 10 of 321